Literature DB >> 34156515

[Diagnostic markers in urology].

Marie C Hupe1, Marie C Hempel2, Severin Rodler3, Maria Frantzi4, Harald Mischak4,5, Axel S Merseburger2, Christian G Stief3, Michael Chaloupka6.   

Abstract

Cancer diagnostics can be supplemented by disease-related biomarkers. In the course of modern patient-tailored cancer treatment, the importance of correct risk stratification, prognosis and monitoring has significantly increased. In recent years, a multitude of biomarkers and related test procedures have emerged to fulfil this purpose. The following review article summarizes the most recent developments with respect to the use of biomarkers in the diagnostics of urological cancers.

Entities:  

Keywords:  Biomarkers; Diagnostics; Liquid biopsy; Non-invasive; Risk stratification

Year:  2021        PMID： 34156515     DOI： 10.1007/s00120-021-01568-8

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  39 in total

1.  Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.

Authors:  Leander Van Neste; Rianne J Hendriks; Siebren Dijkstra; Geert Trooskens; Erik B Cornel; Sander A Jannink; Hans de Jong; Daphne Hessels; Frank P Smit; Willem J G Melchers; Gisèle H J M Leyten; Theo M de Reijke; Henk Vergunst; Paul Kil; Ben C Knipscheer; Christina A Hulsbergen-van de Kaa; Peter F A Mulders; Inge M van Oort; Wim Van Criekinge; Jack A Schalken
Journal:  Eur Urol       Date:  2016-04-20       Impact factor: 20.096

2.  A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.

Authors:  Katharina Braun; Daniel D Sjoberg; Andrew J Vickers; Hans Lilja; Anders S Bjartell
Journal:  Eur Urol       Date:  2015-05-13       Impact factor: 20.096

Review 3.  Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.

Authors:  Joshua J Fenton; Meghan S Weyrich; Shauna Durbin; Yu Liu; Heejung Bang; Joy Melnikow
Journal:  JAMA       Date:  2018-05-08       Impact factor: 56.272

4.  A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

Authors:  William J Catalona; Alan W Partin; Martin G Sanda; John T Wei; George G Klee; Chris H Bangma; Kevin M Slawin; Leonard S Marks; Stacy Loeb; Dennis L Broyles; Sanghyuk S Shin; Amabelle B Cruz; Daniel W Chan; Lori J Sokoll; William L Roberts; Ron H N van Schaik; Isaac A Mizrahi
Journal:  J Urol       Date:  2011-03-17       Impact factor: 7.450

Review 5.  American Cancer Society guideline for the early detection of prostate cancer: update 2010.

Authors:  Andrew M D Wolf; Richard C Wender; Ruth B Etzioni; Ian M Thompson; Anthony V D'Amico; Robert J Volk; Durado D Brooks; Chiranjeev Dash; Idris Guessous; Kimberly Andrews; Carol DeSantis; Robert A Smith
Journal:  CA Cancer J Clin       Date:  2010-03-03       Impact factor: 508.702

6.  PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.

Authors:  Christian G Ramos; Raul Valdevenito; Ivonne Vergara; Patricio Anabalon; Catherine Sanchez; Juan Fulla
Journal:  Urol Oncol       Date:  2012-06-09       Impact factor: 3.498

7.  Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.

Authors:  Massimo Lazzeri; Alexander Haese; Alberto Abrate; Alexandre de la Taille; Joan Palou Redorta; Thomas McNicholas; Giovanni Lughezzani; Giuliana Lista; Alessandro Larcher; Vittorio Bini; Andrea Cestari; Nicolòmaria Buffi; Markus Graefen; Olivier Bosset; Philippe Le Corvoisier; Alberto Breda; Pablo de la Torre; Linda Fowler; Jacques Roux; Giorgio Guazzoni
Journal:  BJU Int       Date:  2013-08       Impact factor: 5.588

8.  PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

Authors:  Leonard S Marks; Yves Fradet; Ina Lim Deras; Amy Blase; Jeannette Mathis; Sheila M J Aubin; Anthony T Cancio; Marie Desaulniers; William J Ellis; Harry Rittenhouse; Jack Groskopf
Journal:  Urology       Date:  2007-03       Impact factor: 2.649

9.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

Authors:  Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Maria De Santis; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Vsevolod B Matveev; Paul C Moldovan; Roderick C N van den Bergh; Thomas Van den Broeck; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Philip Cornford
Journal:  Eur Urol       Date:  2016-08-25       Impact factor: 20.096

10.  DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

Authors:  Daphne Hessels; Jacqueline M T Klein Gunnewiek; Inge van Oort; Herbert F M Karthaus; Geert J L van Leenders; Bianca van Balken; Lambertus A Kiemeney; J Alfred Witjes; Jack A Schalken
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.